CEACAM5 and metastatic neoplasm: Thanks to the early decreases in ctDNA amounts in patients with metastatic disease, they demonstrated that plasma tumor DNA is a better marker for recurrence than carcinoembryonic antigen (CEA), which is currently used in the clinical setting.